{"id":"W4389247829","doi":"10.1182/blood-2023-173692","title":"Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Follicular lymphoma; Internal medicine; Clinical endpoint; Refractory (planetary science); Phases of clinical research; Surrogate endpoint; Adverse effect; Regimen; Gastroenterology; Chemotherapy regimen; Oncology; Surgery; Lymphoma; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004814895,0.0003590324,0.0006520337,0.0004452526,0.00014667,0.00007930421,0.0001740696,0.0001393043,0.0005448067],"category_scores_gemma":[0.0001564946,0.000263203,0.00009507592,0.000853742,0.00009458556,0.000158163,0.000096772,0.0002198641,0.00004078453],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001056757,"about_ca_system_score_gemma":0.0002691302,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004440532,"about_ca_topic_score_gemma":0.0005470425,"domain_scores_codex":[0.9971987,0.0003005425,0.0004474051,0.0007198142,0.0007436821,0.000589865],"domain_scores_gemma":[0.9985142,0.0002838609,0.00009085792,0.0006883304,0.0001507426,0.0002720401],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2027137,0.01215059,0.6767707,0.0000360776,0.001426788,0.001540723,0.0182246,8.141244e-7,0.04458343,9.851274e-7,0.0002494031,0.04230217],"study_design_scores_gemma":[0.196792,0.0307371,0.7603176,0.0003089365,0.0002195164,0.000009101213,0.003102304,0.00002514731,0.005444872,0.00002104278,0.002561196,0.0004612475],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959715,0.0003881123,0.000002876766,0.0002139354,0.00007627226,0.003008982,0.00009469603,0.0001641555,0.00007946881],"genre_scores_gemma":[0.991315,0.0001399867,0.0002922797,0.0001909944,0.00007528701,0.0005314546,0.00003966243,0.0001155638,0.007299748],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08354683,"threshold_uncertainty_score":0.999982,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0162297430801629,"score_gpt":0.2860685783572566,"score_spread":0.2698388352770937,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}